Literature DB >> 17620156

Oculocutaneous albinism in a rural community of South Africa: a population genetic study.

P M Lund1, T G Maluleke, I Gaigher, M J Gaigher.   

Abstract

Oculocutaneous albinism type II (OCA2), the most common form of albinism worldwide, is prevalent throughout sub-Saharan Africa. The hypopigmentory phenotype distinguishes affected individuals as 'different' in a black population, resulting in problems of social acceptance and integration. Health issues include constant, lifelong sun-induced skin damage and poor vision. This study determined the frequency and distribution of albinism among the Vhavenda ethnic group living in the relatively low-income north of South Africa in a clan-oriented society. A retrospective study of birth records from regional hospitals gave an incidence of OCA of 1 in 1970, whereas a survey of mainstream schools gave a frequency of only one pupil with albinism in 13,319 as most affected children attended the regional special school. A community-based field study of 35 rural villages gave a prevalence of 1 in 2239 for OCA. One clan, the Vhatavhatsindi, had a significantly higher frequency of 1 in 832. This epidemiological study provides the necessary data for developing health care and welfare system for families affected by albinism in this region.

Entities:  

Mesh:

Year:  2007        PMID: 17620156     DOI: 10.1080/03014460701401261

Source DB:  PubMed          Journal:  Ann Hum Biol        ISSN: 0301-4460            Impact factor:   1.533


  3 in total

Review 1.  Pigmentation and vision: Is GPR143 in control?

Authors:  Brian S McKay
Journal:  J Neurosci Res       Date:  2018-05-14       Impact factor: 4.164

2.  Lack of adequate sun protection for children with oculocutaneous albinism in South Africa.

Authors:  Patricia M Lund; Julie S Taylor
Journal:  BMC Public Health       Date:  2008-06-30       Impact factor: 3.295

3.  Living with albinism in an African community: exploring the challenges of persons with albinism in Lilongwe District, Malawi.

Authors:  Thandiwe Tambala-Kaliati; Emmanuel Brenyah Adomako; Kwabena Frimpong-Manso
Journal:  Heliyon       Date:  2021-05-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.